In DTC TV, longer doesn't have to mean less memorable, says Nielsen

Share this article:
In DTC TV, longer doesn't have to mean less memorable, says Nielsen
In DTC TV, longer doesn't have to mean less memorable, says Nielsen
Prescription drug advertisers are running longer broadcast spots to accommodate more expansive fair balance statements, a Nielsen IAG analysis suggests, as 75-second spots proliferate.

That's not necessarily bad news for pharma firms, said Nielsen healthcare practice SVP Fariba Zamaniyan, noting that several 75-second spots made the firm's “Most recalled” list.

“This ranking shows that it doesn't necessarily mean people are going to tune it out,” said Zamaniyan. “It always comes down to the creative.”

Ads for Boehringer Ingelheim's Flomax BPH treatment were the most-recalled spots for the 2008-2009 TV season, according to Nielsen.

The 45- and 60-second ads, which show men at a baseball game and on a golf course frequenting bathrooms as an announcer lists symptoms of urinary incontinence due to BPH, benefited from standout, relevant and consistent visuals, said Zamaniyan.

Tied for second place in the ranking were 60-second spots for Lilly's “What are you waiting for?” Cialis effort and Merck's “One less” campaign for Gardasil. Rounding out the top five were spots for Wyeth's Pristiq (:75), Bristol- Myers Squibb/Sanofi-Aventis' Plavix (:60 and :75), and BMS's Orencia (:75).

The list pours cold water on the notion that treatments for symptomatic conditions are advantaged over those for asymptomatic ones when it comes to consumer advertising, said Zamaniyan, pointing to memorable spots for Plavix and Gardasil.

“There's this perception out there that because you don't have packaging, you need symptoms to make advertising more tangible, to give the viewer something to see and feel and relate to,” said Zamaniyan. “This dispels the myth that you have to have a disease state with visible symptoms in order to have memorable advertising.”

The online survey draws from a pool of 6,000 daily respondents.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...